- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Cidofovir, Probenecid
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 7
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 1,620
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2
- Interventions
- RNA antisense oligonucleotide for intravitreal injection
- Drug
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
- Conditions
- Geographic Atrophy, Macular Degeneration
- Interventions
- Avacincaptad pegol (ACP)
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more
- Conditions
- Retinal Dystrophies, Healthy
- Interventions
- Head-Mounted Display
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- A History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Macular Degeneration
- Interventions
- rhuFab V2 (ranibizumab)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 70
- States / cities
- Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more
- Conditions
- Retinoblastoma
- Interventions
- Melphalan
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 4 Months and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
- Interventions
- Proparacaine, Conjunctival culture
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Retinal Neovascularization
- Interventions
- Squalamine Lactate ophthalmic solution 0.2%
- Drug
- Lead sponsor
- Elman Retina Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
- Conditions
- Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Boston, Massachusetts
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- smaller incision, new generation implantable miniature telescope (SING-IMT)
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
- Conditions
- Macular Degeneration, Retinal Drusen
- Interventions
- Pascal Retinal Laser Photocoagulator
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Stargardt Disease
- Interventions
- RTx-021
- Genetic
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Bakersfield, California • Pittsburgh, Pennsylvania • Bellaire, Texas
- Conditions
- Macular Disease
- Interventions
- Platform for Administering Eye-movement Control Training
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Anemia, Retinopathy
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Kresge Eye Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Visudyne, Kenalog
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
- Interventions
- Retinal and Choroidal Imaging
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetic Macular Edema
- Interventions
- Octreotide (drug), Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
- Drug
- Lead sponsor
- Lejla Vajzovic, MD, FASRS
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Macular Edema
- Interventions
- GSK2798745
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Sacramento, California • Lake Worth, Florida • Winter Haven, Florida + 3 more
- Conditions
- Macular Degeneration
- Interventions
- MSI-1256F (Squalamine Lactate)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Plymouth Meeting, Pennsylvania
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
- Interventions
- Aflibercept, foselutoclax
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more